Register | Login

Contain any new studies withhuman or animal subjects performed by any of the authors.OBINUTUZUMAB, A NOVEL HUMANIZED TYPE II MABObinutuzumab (GA101) is a novel, type II, glycoengineered, humanized anti-CD20 mAb that has been developed to address the need for novel therapeutics with higher activity than rituximab. The glycoengineering process post-translational used in thedevelopment of this agent

Who Voted for this Story


Comments



Instant Approval Social Bookmarking Websites

http://www.247prever.com/

http://ib2biz.com/

http://247ebook.co.uk/

http://savelivelife.com/

http://hollywoodbollywood.me/

http://congressdigital.com/

http://marketing.ib2biz.com/



Pligg is an open source content management system that lets you easily create your own social network.

Username:

Password:

Remember: